Masimo and Philips licensing agreement brings Masimo NomoLine®
Capnography and O3® Regional Oximetry to select Philips patient
monitors
May 27, 2020
Amsterdam, the Netherlands and Irvine California –
Masimo (NASDAQ: MASI) and Royal Philips (NYSE: PHG; AEX:
PHIA), both global leaders in patient monitoring, announced today
that they have reinforced their partnership, whereby Philips will
integrate additional Masimo measurement technologies into select
IntelliVue® MX-series multi-parameter monitors, to help clinicians
assess cerebral oximetry and ventilation status.
Core Masimo noninvasive measurements, such as SET®
Measure-through Motion and Low Perfusion™ pulse oximetry and
advanced rainbow SET® Pulse CO-Oximetry parameters like noninvasive
hemoglobin (SpHb®), have long been available on a wide range of
Philips multi-parameter monitors.
In 2016, Masimo and Philips entered into a multi-year business
partnership involving both companies’ innovations in patient
monitoring and therapy solutions. Now, in 2020, Philips becomes one
of Masimo’s first industry partners to launch additional advanced
Masimo measurements, NomoLine and O3, in their own patient
monitors, sharing Masimo’s expertise in capnography and regional
cerebral oximetry with caregivers and patients around the
world.
NomoLine capnography and O3 regional oximetry measurements are
available now on Philips MX500 and MX550 monitors [1] in select
markets [2] throughout the world, and are also available directly
from Masimo on its Root® Patient Monitoring and Connectivity
Platform and when connected to select Philips patient monitors via
Philips’ IntelliBridge module:
- NomoLine “no-moisture” sampling lines are designed for low-flow
applications and can be used in a variety of clinical scenarios and
care settings, on both intubated and non-intubated patients of all
ages, in both low- and high-humidity applications.
- O3 regional oximetry may help clinicians monitor cerebral
oxygenation in situations in which pulse oximetry alone may not be
fully indicative of the oxygen in the brain.
“As global leader in health technology, we are delighted to
reinforce our partnership with Masimo, bringing their advanced
measurements to our innovative IntelliVue patient monitors, thereby
making them even more versatile,” said Frans van Houten, CEO of
Royal Philips. “Our customers expect integrated solutions to help
them address the quadruple aim of healthcare. The complementary
strengths of Philips and Masimo allow us to offer, reliable
ventilation and regional oximetry solutions, which we expect will
help clinicians deliver even better patient care.”
“Combining our expertise in noninvasive monitoring and signal
processing technologies with Philips’ expertise in integrated
patient monitoring and therapy solutions is a win-win for patients
and clinicians alike,” said Joe Kiani, Founder and CEO of Masimo.
“We are proud that Philips, recognizing our expertise in this
clinical space, has chosen to make our innovative O3 and NomoLine
platforms available to their customers. We look forward to
continuing our partnership with a focus on improving patient
outcomes and reducing the cost of care.”
[1] Pending 510k, not available for sale in the
USA[2] Not for sale in Albania, American Samoa, Bosnia
and Herzegovina, Brazil, Belarus, Canada, China, Columbia, Costa
Rica, Algeria, Egypt (O3 is available for sale), Guam, Hong Kong,
Indonesia, , Iran, Japan, Kenya, Cambodia, Korea, Kazakhstan, Sri
Lanka, Morocco (O3 is available for sale), Montenegro, Macedonia,
Northern Mariana Islands, Mexico, Malaysia, Panama, Peru,
Philippines, Puerto Rico, Serbia, Russian Federation, Saudi Arabia,
Singapore, Syrian Arab Republic, Thailand, Turkey, Taiwan, Ukraine,
Venezuela, U.S. Virgin Islands, Vietnam, South Africa.
For further information, please contact:
Steve KlinkPhilips Global Press OfficeTel.: +31 6
10888824E-mail: steve.klink@philips.com
Evan LambMasimoTel.: +1 949 396 3376E-mail: elamb@masimo.com
About Royal PhilipsRoyal Philips (NYSE: PHG,
AEX: PHIA) is a leading health technology company focused on
improving people's health and enabling better outcomes across the
health continuum from healthy living and prevention, to diagnosis,
treatment and home care. Philips leverages advanced technology and
deep clinical and consumer insights to deliver integrated
solutions. Headquartered in the Netherlands, the company is a
leader in diagnostic imaging, image-guided therapy, patient
monitoring and health informatics, as well as in consumer health
and home care. Philips generated 2019 sales of EUR 19.5 billion and
employs approximately 81,000 employees with sales and services in
more than 100 countries. News about Philips can be found at
www.philips.com/newscenter.
About MasimoMasimo (NASDAQ: MASI) is a global medical
technology company that develops and produces a wide array of
industry-leading monitoring technologies, including innovative
measurements, sensors, patient monitors, and automation and
connectivity solutions. Our mission is to improve patient outcomes
and reduce the cost of care. Masimo SET® Measure-through Motion and
Low Perfusion™ pulse oximetry, introduced in 1995, has been shown
in over 100 independent and objective studies to outperform other
pulse oximetry technologies [1]. Masimo SET® has also been shown to
help clinicians reduce severe retinopathy of prematurity in
neonates [2], improve CCHD screening in newborns [3], and, when
used for continuous monitoring with Masimo Patient SafetyNet™ in
post-surgical wards, reduce rapid response team activations, ICU
transfers, and costs [4-6]. Masimo SET® is estimated to be used on
more than 200 million patients in leading hospitals and other
healthcare settings around the world [7], and is the primary pulse
oximetry at 9 of the top 10 hospitals according to the 2019-20 U.S.
News and World Report Best Hospitals Honor Roll [8]. Masimo
continues to refine SET® and in 2018, announced that SpO2 accuracy
on RD SET® sensors during conditions of motion has been
significantly improved, providing clinicians with even greater
confidence that the SpO2 values they rely on accurately reflect a
patient’s physiological status. In 2005, Masimo introduced rainbow®
Pulse CO-Oximetry technology, allowing noninvasive and continuous
monitoring of blood constituents that previously could only be
measured invasively, including total hemoglobin (SpHb®), oxygen
content (SpOC™), carboxyhemoglobin (SpCO®), methemoglobin (SpMet®),
Pleth Variability Index (PVi®), RPVi™ (rainbow® PVi), and Oxygen
Reserve Index (ORi™). In 2013, Masimo introduced the Root® Patient
Monitoring and Connectivity Platform, built from the ground up to
be as flexible and expandable as possible to facilitate the
addition of other Masimo and third-party monitoring technologies;
key Masimo additions include Next Generation SedLine® Brain
Function Monitoring, O3® Regional Oximetry, and ISA™ Capnography
with NomoLine® sampling lines. Masimo’s family of continuous and
spot-check monitoring Pulse CO-Oximeters® includes devices designed
for use in a variety of clinical and non-clinical scenarios,
including tetherless, wearable technology, such as Radius-7® and
Radius PPG™, portable devices like Rad-67™, fingertip pulse
oximeters like MightySat® Rx, and devices available for use both in
the hospital and at home, such as Rad-97®. Masimo hospital
automation and connectivity solutions are centered around the Iris®
platform, and include Iris Gateway®, Patient SafetyNet, Replica™,
Halo ION™, UniView™, and Masimo SafetyNet™. Additional information
about Masimo and its products may be found at www.masimo.com.
Published clinical studies on Masimo products can be found at
www.masimo.com/evidence/featured-studies/feature/.
[1] Published clinical studies on pulse oximetry and
the benefits of Masimo SET® can be found on our website at
http://www.masimo.com. Comparative studies include independent and
objective studies which are comprised of abstracts presented at
scientific meetings and peer-reviewed journal
articles.[2] Castillo A et al. Prevention of
Retinopathy of Prematurity in Preterm Infants through Changes in
Clinical Practice and SpO2 Technology. Acta Paediatr. 2011
Feb;100(2):188-92.[3] de-Wahl Granelli A et al. Impact
of pulse oximetry screening on the detection of duct dependent
congenital heart disease: a Swedish prospective screening study in
39,821 newborns. BMJ. 2009;Jan 8;338.[4] Taenzer AH et
al. Impact of pulse oximetry surveillance on rescue events and
intensive care unit transfers: a before-and-after concurrence
study. Anesthesiology. 2010:112(2):282-287.[5] Taenzer
A et al. Postoperative Monitoring – The Dartmouth Experience.
Anesthesia Patient Safety Foundation Newsletter. Spring-Summer
2012.[6] McGrath SP et al. Surveillance Monitoring
Management for General Care Units: Strategy, Design, and
Implementation. The Joint Commission Journal on Quality and Patient
Safety. 2016 Jul;42(7):293-302.[7] Estimate: Masimo
data on file.[8]
http://health.usnews.com/health-care/best-hospitals/articles/best-hospitals-honor-roll-and-overview.
Forward-Looking Statements: Masimo This press
release includes forward-looking statements as defined in Section
27A of the Securities Act of 1933 and Section 21E of the Securities
Exchange Act of 1934, in connection with the Private Securities
Litigation Reform Act of 1995. These forward-looking statements
include, among others, statements regarding the potential
effectiveness of Masimo NomoLine®, O3®, SET®, rainbow SET®, and
Root®. These forward-looking statements are based on current
expectations about future events affecting us and are subject to
risks and uncertainties, all of which are difficult to predict and
many of which are beyond our control and could cause our actual
results to differ materially and adversely from those expressed in
our forward-looking statements as a result of various risk factors,
including, but not limited to: risks related to our assumptions
regarding the repeatability of clinical results; risks related to
our belief that Masimo's unique noninvasive measurement
technologies, including Masimo NomoLine, O3, SET®, rainbow SET®,
and Root, contribute to positive clinical outcomes and patient
safety; risks related to our belief that Masimo noninvasive medical
breakthroughs provide cost-effective solutions and unique
advantages; as well as other factors discussed in the "Risk
Factors" section of our most recent reports filed with the
Securities and Exchange Commission ("SEC"), which may be obtained
for free at the SEC's website at www.sec.gov. Although we believe
that the expectations reflected in our forward-looking statements
are reasonable, we do not know whether our expectations will prove
correct. All forward-looking statements included in this press
release are expressly qualified in their entirety by the foregoing
cautionary statements. You are cautioned not to place undue
reliance on these forward-looking statements, which speak only as
of today's date. We do not undertake any obligation to update,
amend or clarify these statements or the "Risk Factors" contained
in our most recent reports filed with the SEC, whether as a result
of new information, future events or otherwise, except as may be
required under the applicable securities laws.
- Philips MX500 patient monitor
Koninklijke Philips NV (EU:PHIA)
Gráfica de Acción Histórica
De Mar 2024 a Abr 2024
Koninklijke Philips NV (EU:PHIA)
Gráfica de Acción Histórica
De Abr 2023 a Abr 2024